GALA-RIF, an 18-month investigator-initiated, randomised, double-blind, placebo-controlled trial, showed that rifaximin-α did not lead to regression of liver fibrosis in patients with alcohol-related liver disease. The gene discussed is GLA; the disease is Hepatic fibrosis.